ExpertiseUpdated on 13 May 2025

Building AI POC in a few days

Anna Elwart

CEO at EL Passion

Warsaw, Poland

About

We help to translate research results into business ideas. Our goal is to test market potential with limited upfront cost and saving time. If you fail quick, you learn faster and get to the right idea faster. If you have a proof of market potential - it's easier to get talent and funds for your initiative.

Field

  • Healthcare
  • ICT Industry and Services

Organisation

EL Passion

Freelancer/Consulting

Warsaw, Poland

Similar opportunities

  • Project cooperation

    Tech Opportunities

    Kasia Kulikowska

    Senior EU Grants Specialist at FundingBox

    Warsaw, Poland

  • Project cooperation

    EIC Pathfinder / HE Cluster Health projects for EU Hop On Grant application

    Ricardo Viais, PhD

    Project Manager at Colab AccelBio

    Lisbon, Portugal

  • Project cooperation

    ACRE AI

    • Partner seeks Consortium/Coordinator
    • Consortium/Coordinator seeks Partners
    • HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies
    • Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
    • HORIZON-CL4-2025-03-HUMAN-18: GenAI4EU central Hub (CSA) (AI/Data/Robotics Partnership)
    • HORIZON-HLTH-2025-03-TOOL-01-two-stage: Enhancing cell therapies with genomic techniques
    • HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
    • HORIZON-CL4-2025-04-DATA-03: Software Engineering for AI and generative AI (RIA) (AI/Data/Robotics Partnership)
    • HORIZON-CL4-2025-04-DIGITAL-EMERGING-06: Challenge-Driven GenAI4EU Booster (RIA) (AI/Data/Robotics Partnership)
    • HORIZON-CL4-2025-03-DATA-13: Fostering Innovative and Compliant Data Ecosystems (IA) (AI, Data and Robotics Partnership)
    • Cluster Health (CL1): HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response
    • HORIZON-CL4-2025-04-DATA-02: Empowering AI/generative AI along the Cognitive Computing continuum (RIA) (AI/Data/Robotics Partnership)
    • HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices
    • Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
    • Cluster Health (CL1): HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
    • Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders
    • Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
    • Cluster Health (CL1): HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
    • HORIZON-HLTH-2025-01-IND-03: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices
    • Cancer Mission: HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers
    • HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
    • HORIZON-HLTH-2025-01-DISEASE-01: Randomised controlled trials to test safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
    • Cluster Health (CL1): HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
    • HORIZON-HLTH-2025-03-DISEASE-06-two-stage: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)

    Robert Lugowski

    CEO at CliniNote

    Warsaw, Poland